A Simple and Fast Protocol to Detect Nucleophosmin 1 (NPM1) Mutation and Fms-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3/ITD): Optimizing Laboratory Routine
Authors:
- Alessandra Helena da Silva HellwigAHAlessandra Helena da Silva Hellwig
- Gisele Menezes EwaldGEGisele Menezes Ewald
- Grazielle Motta RodriguesGRGrazielle Motta Rodrigues
- William Latosinski MatosWMWilliam Latosinski Matos
- Juliana BergmannJBJuliana Bergmann
- Viviane Horn de MeloVMViviane Horn de Melo
- Rodrigo Minuto PaivaRPRodrigo Minuto Paiva
- Dariane Castro PereiraDPDariane Castro Pereira
- Eduardo Wandame GomezEGEduardo Wandame Gomez
Open Access
- 3 April 2026
- journal article
- research article
- Published by MDPI AG in Methods and Protocols
- Vol. 9 (2) , 59
Abstract
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy. AML classification is currently based on cytogenetic and molecular alterations as well as immunophenotyping, although risk stratification still relies primarily on cytogenetic findings. However, approximately 45% of AML patients present with a normal karyotype, which makes accurate risk classification and treatment stratification more challenging. Therefore, the identification of molecular prognostic markers described in the literature has become essential in routine diagnostic laboratories, enabling the more precise categorization of patients into risk groups. In this study, we present a simple, rapid, step-by-step multiplex PCR protocol combined with capillary electrophoresis for the detection of two of the most prevalent molecular alterations in AML: nucleophosmin 1 (NPM1) mutations and Fms-like tyrosine kinase 3 internal tandem duplications (FLT3/ITD). This protocol provides a practical workflow that can assist diagnostic laboratories in implementing and optimizing multiplex mutation detection in routine practice.Keywords
Funding Information
- Fundo de Incentivo à Pesquisa e Eventos (FIPE 2022-0410)
This publication has 17 references indexed in Scilit:
- Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2023
- NPM1: not present? Mark!Blood, 2021
- NPM1 and FLT3-ITD/TKD Gene Mutations in Acute Myeloid LeukemiaInternational Journal of Hematology-Oncology and Stem Cell Research, 2021
- FLT3mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)Blood, 2018
- Clinical implications of molecular markers in acute myeloid leukemiaEuropean Journal of Haematology, 2018
- Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 MutationsThe Journal of Molecular Diagnostics, 2017
- Molecular and cytogenetic abnormalities in acute myeloid leukemia: review and case studiesEinstein (São Paulo), 2011
- Importância da detecção das mutações no gene FLT3 e no gene NPM1 na leucemia mieloide aguda - Classificação da Organização Mundial de Saúde 2008Revista Brasileira de Ginecologia e Obstetrícia, 2010
- Minimal residual disease levels assessed by NPM1 mutation–specific RQ-PCR provide important prognostic information in AMLBlood, 2009
- A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogeneticsBritish Journal of Haematology, 2008